Soluble DPP-4 up-regulates toll-like receptors and augments inflammatory reactions, which are ameliorated by vildagliptin or mannose-6-phosphate

Metabolism: Clinical and Experimental

Volumn 65, Issue 2, 2016, Pages 89-101

  Lee, Dong Sung ^a   Lee, Eun Sol ^b   Alam, Md Morshedul ^c   Jang, Jun Hyeog ^d   Lee, Ho Sub ^b   Oh, Hyuncheol ^b   Kim, Youn Chul ^b   Manzoor, Zahid ^e   Koh, Young Sang ^e   Kang, Dae Gil ^b   Lee, Dae Ho ^b  

^a Konkuk University   (South Korea)

^b Wonkwang University   (South Korea)

^c TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d Inha University School of Medicine   (South Korea)

^e Jeju National University School of Medicine   (South Korea)

Author keywords

Dipeptidyl peptidase 4; Inflammation; Macrophages; Mannose 6 phosphate; Toll like receptor; Vildagliptin

Indexed keywords

BISINDOLYLMALEIMIDE; DIPEPTIDYL PEPTIDASE IV; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 12; INTERLEUKIN 6; MANNOSE 6 PHOSPHATE; PROTEIN P40; STRESS ACTIVATED PROTEIN KINASE; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; VILDAGLIPTIN; ADAMANTANE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; LIPOPOLYSACCHARIDE; MANNOSE PHOSPHATE; MANNOSE-6-PHOSPHATE; MESSENGER RNA; NITRILE; PYRROLIDINE DERIVATIVE;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL LINE RAW 264.7; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; INFLAMMATION; MACROPHAGE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; SIGNAL TRANSDUCTION; WESTERN BLOTTING; WHITE ADIPOSE TISSUE; ANALOGS AND DERIVATIVES; ANIMAL; C57BL MOUSE; CELL CULTURE; GENETICS; METABOLISM; PHYSIOLOGY;

ADAMANTANE; ANIMALS; CELLS, CULTURED; DIPEPTIDYL PEPTIDASE 4; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; INFLAMMATION; LIPOPOLYSACCHARIDES; MANNOSEPHOSPHATES; MICE; MICE, INBRED C57BL; NF-KAPPA B; NITRIC OXIDE SYNTHASE TYPE II; NITRILES; PYRROLIDINES; RNA, MESSENGER; TOLL-LIKE RECEPTORS;

EID: 84959522726     PISSN: 00260495     EISSN: 15328600     Source Type: Journal    
DOI: 10.1016/j.metabol.2015.10.002     Document Type: Article

References (38)

1. E.E. Mulvihill, and D.J. Drucker Pharmacology, physiology and mechanisms of action of dipeptidyl peptidase-4 inhibitors Endocr Rev 35 2014 992 1019
2. E.Y. Choe, Y. Cho, Y. Choi, Y. Yun, H.J. Wang, O. Kwon, and et al. The effect of DPP-4 inhibitors on metabolic parameters in patients with type 2 diabetes Diabetes Metab J 38 2014 211 219
3. A.M. McKillop, N.A. Duffy, J.R. Lindsay, F.P. O'Harte, P.M. Bell, and P.R. Flatt Decreased dipeptidyl peptidase-IV activity and glucagon-like peptide-1(7-36)amide degradation in type 2 diabetic subjects Diabetes Res Clin Pract 79 2008 79 85
4. R. Mentlein Dipeptidyl-peptidase IV, (CD26) - role in the inactivation of regulatory peptides Regul Pept 85 1999 9 24
5. N.H. Kim, T. Yu, and D.H. Lee The nonglycemic actions of dipeptidyl peptidase-4 inhibitors Biomed Res Int 2014 2014 368703
6. A.R. Aroor, J.R. Sowers, G. Jia, and V.G. DeMarco Pleiotropic effects of the dipeptidylpeptidase-4 inhibitors on the cardiovascular system Am J Physiol Heart Circ Physiol 307 2014 H477 H492
7. S. Lim, S.H. Choi, H. Shin, B.J. Cho, H.S. Park, B.Y. Ahn, and et al. Effect of a dipeptidyl peptidase-IV inhibitor, des-fluoro-sitagliptin, on neointimal formation after balloon injury in rats PLoS One 7 2012 e35007
8. M.D. Gorrell, V. Gysbers, and G.W. McCaughan CD26: a multifunctional integral membrane and secreted protein of activated lymphocytes Scand J Immunol 54 2001 249 264
9. K. Ohnuma, N. Takahashi, T. Yamochi, O. Hosono, N.H. Dang, and C. Morimoto Role of CD26/dipeptidyl peptidase IV in human T cell activation and function Front Biosci 13 2008 2299 2310
10. J.S. Duke-Cohan, C. Morimoto, J.A. Rocker, and S.F. Schlossman A novel form of dipeptidylpeptidase IV found in human serum. Isolation, characterization, and comparison with T lymphocyte membrane dipeptidylpeptidase IV (CD26) J Biol Chem 270 1995 14107 14114
11. S.A. Lee, Y.R. Kim, E.J. Yang, E.J. Kwon, S.H. Kim, S.H. Kang, and et al. CD26/DPP4 levels in peripheral blood and T cells in patients with type 2 diabetes mellitus J Clin Endocrinol Metab 98 2013 2553 2561
12. D. Lamers, S. Famulla, N. Wronkowitz, S. Hartwig, S. Lehr, D.M. Ouwens, and et al. Dipeptidyl peptidase 4 is a novel adipokine potentially linking obesity to the metabolic syndrome Diabetes 60 2011 1917 1925
13. H. Sell, M. Bluher, N. Kloting, R. Schlich, M. Willems, F. Ruppe, and et al. Adipose dipeptidyl peptidase-4 and obesity: correlation with insulin resistance and depot-specific release from adipose tissue in vivo and in vitro Diabetes Care 36 2013 4083 4090
14. D. Rohrborn, J. Eckel, and H. Sell Shedding of dipeptidyl peptidase 4 is mediated by metalloproteases and up-regulated by hypoxia in human adipocytes and smooth muscle cells FEBS Lett 588 2014 3870 3877
15. Y. Ishibashi, T. Matsui, S. Maeda, Y. Higashimoto, and S.I. Yamagishi Advanced glycation end products evoke endothelial cell damage by stimulating soluble dipeptidyl peptidase-4 production and its interaction with mannose 6-phosphate/insulin-like growth factor II receptor Cardiovasc Diabetol 12 2013 125
16. H. Ikushima, Y. Munakata, T. Ishii, S. Iwata, M. Terashima, H. Tanaka, and et al. Internalization of CD26 by mannose 6-phosphate/insulin-like growth factor II receptor contributes to T cell activation Proc Natl Acad Sci U S A 97 2000 8439 8444
17. N. Ervinna, T. Mita, E. Yasunari, K. Azuma, R. Tanaka, S. Fujimura, and et al. Anagliptin, a DPP-4 inhibitor, suppresses proliferation of vascular smooth muscles and monocyte inflammatory reaction and attenuates atherosclerosis in male apo E-deficient mice Endocrinology 154 2013 1260 1270
18. N. Wronkowitz, S.W. Gorgens, T. Romacho, L.A. Villalobos, C.F. Sanchez-Ferrer, C. Peiro, and et al. Soluble DPP4 induces inflammation and proliferation of human smooth muscle cells via protease-activated receptor 2 Biochim Biophys Acta 2014 1842 1613 1621
19. K. Ohnuma, M. Uchiyama, T. Yamochi, K. Nishibashi, O. Hosono, N. Takahashi, and et al. Caveolin-1 triggers T-cell activation via CD26 in association with CARMA1 J Biol Chem 282 2007 10117 10131
20. J. Zhong, X. Rao, J. Deiuliis, Z. Braunstein, V. Narula, J. Hazey, and et al. A potential role for dendritic cell/macrophage-expressing DPP4 in obesity-induced visceral inflammation Diabetes 62 2013 149 157
21. N.N. Ta, Y. Li, C.A. Schuyler, M.F. Lopes-Virella, and Y. Huang DPP-4 (CD26) inhibitor alogliptin inhibits TLR4-mediated ERK activation and ERK-dependent MMP-1 expression by U937 histiocytes Atherosclerosis 213 2010 429 435
22. K. Ohnuma, T. Yamochi, M. Uchiyama, K. Nishibashi, S. Iwata, O. Hosono, and et al. CD26 mediates dissociation of Tollip and IRAK-1 from caveolin-1 and induces upregulation of CD86 on antigen-presenting cells Mol Cell Biol 25 2005 7743 7757
23. M.A. Titheradge The enzymatic measurement of nitrate and nitrite Methods Mol Biol 100 1998 83 91
24. I. Jialal, H. Kaur, and S. Devaraj Toll-like receptor status in obesity and metabolic syndrome: a translational perspective J Clin Endocrinol Metab 99 2014 39 48
25. A. Makdissi, H. Ghanim, M. Vora, K. Green, S. Abuaysheh, A. Chaudhuri, and et al. Sitagliptin exerts an antinflammatory action J Clin Endocrinol Metab 97 2012 3333 3341
26. M.R. Rizzo, M. Barbieri, R. Marfella, and G. Paolisso Reduction of oxidative stress and inflammation by blunting daily acute glucose fluctuations in patients with type 2 diabetes: role of dipeptidyl peptidase-IV inhibition Diabetes Care 35 2012 2076 2082
27. D.M. Yu, L. Slaitini, V. Gysbers, A.G. Riekhoff, T. Kahne, H.M. Knott, and et al. Soluble CD26/dipeptidyl peptidase IV enhances human lymphocyte proliferation in vitro independent of dipeptidyl peptidase enzyme activity and adenosine deaminase binding Scand J Immunol 73 2011 102 111
28. J. Shirakawa, H. Fujii, K. Ohnuma, K. Sato, Y. Ito, M. Kaji, and et al. Diet-induced adipose tissue inflammation and liver steatosis are prevented by DPP-4 inhibition in diabetic mice Diabetes 60 2011 1246 1257
29. Z. Shah, T. Kampfrath, J.A. Deiuliis, J. Zhong, C. Pineda, Z. Ying, and et al. Long-term dipeptidyl-peptidase 4 inhibition reduces atherosclerosis and inflammation via effects on monocyte recruitment and chemotaxis Circulation 124 2011 2338 2349
30. K. Akita, K. Isoda, K. Shimada, and H. Daida Dipeptidyl-peptidase-4 inhibitor, alogliptin, attenuates arterial inflammation and neointimal formation after injury in low-density lipoprotein (LDL) receptor-deficient mice J Am Heart Assoc 4 2015 e001469
31. E. Boonacker, and C.J. Van Noorden The multifunctional or moonlighting protein CD26/DPPIV Eur J Cell Biol 82 2003 53 73
32. S.A. Kim, W.H. Shim, E.H. Lee, Y.M. Lee, S.H. Beom, E.S. Kim, and et al. Predictive clinical parameters for the therapeutic efficacy of sitagliptin in korean type 2 diabetes mellitus Diabetes Metab J 35 2011 159 165
33. Y. Aso, N. Ozeki, T. Terasawa, R. Naruse, K. Hara, M. Suetsugu, and et al. Serum level of soluble CD26/dipeptidyl peptidase-4 (DPP-4) predicts the response to sitagliptin, a DPP-4 inhibitor, in patients with type 2 diabetes controlled inadequately by metformin and/or sulfonylurea Transl Res 159 2012 25 31
34. Y.G. Kim, S. Hahn, T.J. Oh, S.H. Kwak, K.S. Park, and Y.M. Cho Differences in the glucose-lowering efficacy of dipeptidyl peptidase-4 inhibitors between Asians and non-Asians: a systematic review and meta-analysis Diabetologia 56 2013 696 708
35. M.R. Dasu, S. Devaraj, L. Zhao, D.H. Hwang, and I. Jialal High glucose induces toll-like receptor expression in human monocytes: mechanism of activation Diabetes 57 2008 3090 3098
36. E. Aksoy, M. Goldman, and F. Willems Protein kinase C epsilon: a new target to control inflammation and immune-mediated disorders Int J Biochem Cell Biol 36 2004 183 188
37. C. Hawkes, and S. Kar The insulin-like growth factor-II/mannose-6-phosphate receptor: structure, distribution and function in the central nervous system Brain Res Brain Res Rev 44 2004 117 140
38. L. Kong, X. Shen, L. Lin, M. Leitges, R. Rosario, Y.S. Zou, and et al. PKCbeta promotes vascular inflammation and acceleration of atherosclerosis in diabetic ApoE null mice Arterioscler Thromb Vasc Biol 33 2013 1779 1787